Capstone Therapeutics Corp. (NASDAQ:CAPS) Stock Short Interest Falls 95.9%

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 28,547 shares, a drop of 95.9% from the October 15th total of 696,378 shares. Approximately 5.1% of the shares of the company are short sold. Based on an average trading volume of 63,445 shares, the short-interest ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Capstone Therapeutics Stock Down 7.3%

Shares of CAPS opened at $1.94 on Wednesday. Capstone Therapeutics has a one year low of $1.85 and a one year high of $34.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99. The stock has a 50 day moving average price of $3.96 and a 200 day moving average price of $10.36. The stock has a market capitalization of $1.79 million, a price-to-earnings ratio of -0.02 and a beta of -1.35.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.